130 related articles for article (PubMed ID: 29988078)
21. Precision Medicine, Diabetes, and the U.S. Food and Drug Administration.
Meyer RJ
Diabetes Care; 2016 Nov; 39(11):1874-1878. PubMed ID: 27926889
[TBL] [Abstract][Full Text] [Related]
22. Oncology 2020: a drug development and approval paradigm.
Dhingra K
Ann Oncol; 2015 Nov; 26(11):2347-50. PubMed ID: 26374285
[No Abstract] [Full Text] [Related]
23. How European regulators view foreign data in the approval process.
Breckenridge A; Hudson I
Clin Pharmacol Ther; 2008 Sep; 84(3):311-2. PubMed ID: 18714321
[TBL] [Abstract][Full Text] [Related]
24. Precision Medicines' Impact on Orphan Drug Designation.
Mueller CM; Rao GR; Miller Needleman KI
Clin Transl Sci; 2019 Nov; 12(6):633-640. PubMed ID: 31297924
[TBL] [Abstract][Full Text] [Related]
25. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
26. Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.
Lurie P
MedGenMed; 2006 Oct; 8(4):22. PubMed ID: 17415305
[No Abstract] [Full Text] [Related]
27. Railroading at the FDA.
Nat Med; 2016 Nov; 22(11):1193. PubMed ID: 27824816
[No Abstract] [Full Text] [Related]
28. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
[TBL] [Abstract][Full Text] [Related]
29. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.
Wallach JD; Luxkaranayagam AT; Dhruva SS; Miller JE; Ross JS
BMC Med; 2019 Jun; 17(1):117. PubMed ID: 31203816
[TBL] [Abstract][Full Text] [Related]
30. Oncology drug development: United States Food and Drug Administration perspective.
Hirschfeld S; Pazdur R
Crit Rev Oncol Hematol; 2002 May; 42(2):137-43. PubMed ID: 12007971
[TBL] [Abstract][Full Text] [Related]
31. Beyond the Label: Ensuring That Drug Benefits Outweigh Risks in the Food and Drug Administration's Risk Evaluation and Mitigation Strategy Program.
Epstein MS; Shah ED; Deepak P; Kushnir VM
Am J Gastroenterol; 2019 Jul; 114(7):1017-1019. PubMed ID: 31033521
[No Abstract] [Full Text] [Related]
32. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
Kefalas CH; Ciociola AA
Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
[No Abstract] [Full Text] [Related]
33. Stakeholders discuss biosimilar naming, substitution.
Traynor K
Am J Health Syst Pharm; 2014 Mar; 71(6):446-7. PubMed ID: 24589534
[No Abstract] [Full Text] [Related]
34. Drug safety special: the safety catch.
Wadman M
Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
[No Abstract] [Full Text] [Related]
35. Drugs with FDA accelerated approval often have weak evidence, study finds.
Dyer O
BMJ; 2017 Jun; 357():j2905. PubMed ID: 28615167
[No Abstract] [Full Text] [Related]
36. Drug safety on trial.
Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
[No Abstract] [Full Text] [Related]
37. Correction to: Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations.
Issa AM; Thorogood A; Joly Y; Knoppers BM
Genet Med; 2019 Aug; 21(8):1894-1900. PubMed ID: 30177852
[TBL] [Abstract][Full Text] [Related]
38. Is it rational, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias.
Reiffel JA
J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):333-9. PubMed ID: 11907635
[No Abstract] [Full Text] [Related]
39. More Than One Way to Measure? A Casuistic Approach to Cancer Clinical Trials.
Andreoletti M
Perspect Biol Med; 2018; 61(2):174-190. PubMed ID: 30146517
[TBL] [Abstract][Full Text] [Related]
40. Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study.
Wallach JD; Ciani O; Pease AM; Gonsalves GS; Krumholz HM; Taylor RS; Ross JS
BMC Med; 2018 Mar; 16(1):45. PubMed ID: 29562926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
